Accelerated exposure of phosphatidylserine on lymphocyte populations from patients with systemic lupus erythematosus or rheumatoid arthritis

Christiane Albrecht; Soni Soumian; Raymond Playford; Christopher F. Higgins; Timothy Vyse; James I. Elliott

doi:10.1055/s-0037-1616569

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(05): 989-992
DOI: 10.1055/s-0037-1616569

Case Report

Schattauer GmbH

Accelerated exposure of phosphatidylserine on lymphocyte populations from patients with systemic lupus erythematosus or rheumatoid arthritis

Christiane Albrecht^*

¹MRC-CSC, Membrane Transport Biology, London, UK

^†Current address Physiology Weihenstephan, Technical University Munich, Germany

,

Soni Soumian^*

¹MRC-CSC, Membrane Transport Biology, London, UK

,

Raymond Playford

²Imperial College, Gastroenterology Section, London, UK

,

Christopher F. Higgins

¹MRC-CSC, Membrane Transport Biology, London, UK

,

Timothy Vyse

³Rheumatology Section, London, UK

,

James I. Elliott

¹MRC-CSC, Membrane Transport Biology, London, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Joseph JE, Harrison P, Mackie IJ. et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br. J. Haematol 2001; 115: 451-9.
2 Knijff-Dutmer EA, Koerts J, Nieuwland R. et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002; 46: 1498-503.
3 Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938-45.
4 McClain MT, Arbuckle MR, Heinlen LD. et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1226-32.
5 Gulko PS, Reveille JD, Koopman WJ. et al. Anticardiolipin antibodies in systemic lupus e clinical correlates, HLA associations, and impact on survival. J Rheumatol 1993; 20: 1684-93.
6 Drenkard C, Villa AR, Alarcon-Segovia D. et al. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 1067-72.
7 Cervera R, Piette JC, Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
8 Pierangeli SS, Colden-Stanfield M, Liu X. et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitroand in vivo. Circulation 1999; 99: 1997-2002.
9 Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost 2001; 86: 266-275.
10 Petronilli V, Penzo D, Scorrano L. et al. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings insitu. J Biol Chem 2001; 276: 12030-4.
11 Elliott JI, Higgins CF. IKCa1 activity is required for cell shrinkage, phosphatidylserine translocation and death in T lymphocyte apoptosis. EMBO Rep 2003; 4: 189-94.
12 Elliott I J, Mumford AD, Albrecht C. et al. Characterisation of lymphocyte responses to Ca2+ in Scott syndrome. Thromb Haemost 2004; 91: 412-5.
13 Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 8: 91-103.
14 Hamon Y, Broccardo C, Chambenoit O. et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2000; 2: 399-406.